All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Monoclonal antibodies target antigens expressed by lymphoma cells, making them more selective than chemotherapy. As exemplified by rituximab, which targets CD20 present on B-cells, the Fc portion of the antibody mediates cytotoxicity, while the binding site induces downregulation of the B-cell receptor and apoptosis in CD20+ cells.